


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

**Listing of Claims:**

Claim 1 (original): A substantially pure or isolated oligodeoxynucleotide of at least about 16 nucleotides in length comprising a sequence represented by the following formula:



wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10.

Claim 2 (original): The oligodeoxynucleotide of claim 1, wherein N is about 6.

Claim 3 (original): The oligodeoxynucleotide of claim 1 wherein Pu Py CpG Pu Py comprises phosphodiester bases.

Claim 4 (original): The oligodeoxynucleotide of claim 3 wherein P\_{u1} P\_{y2} C\_{pG} P\_{u3} P\_{y4} are phosphodiester bases.

Claim 5 (original): The oligodeoxynucleotide of claim 3, wherein X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> and X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>(W)<sub>M</sub>(G)<sub>N</sub> comprise phosphodiester bases.

Claim 6 (original): The oligodeoxynucleotide of claim 3, wherein X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> comprises one or more phosphothioate bases.

Claim 7 (original): The oligodeoxynucleotide of claim 3, wherein X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>(W)<sub>M</sub>(G)<sub>N</sub> comprises one or more phosphothioate bases.

Claim 8 (original): The oligodeoxynucleotide of claim 1, wherein X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> Pu Py and Pu Py X<sub>4</sub>X<sub>5</sub>X<sub>6</sub> are self complementary.

Claim 9 (original): The oligodeoxynucleotide of claim 1, wherein X<sub>1</sub>X<sub>2</sub>X<sub>3</sub> AND X<sub>4</sub>X<sub>5</sub>X<sub>6</sub> are self complementary.

Claim 10 (original): The oligodeoxynucleotide of claim 1, wherein Pu Py and Pu Py are self complementary.

Claim 11 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises the sequence

5'-X<sub>1</sub>X<sub>2</sub>TGCATCGATGCAGGGGGG-3' (SEQ ID NO:12);  
5'- X<sub>1</sub>X<sub>2</sub>TGCACCGGTGCAGGGGGG-3' (SEQ ID NO:13);  
5'- X<sub>1</sub>X<sub>2</sub>TGCGTCGACGCAGGGGGG-3'; (SEQ ID NO:)15;  
5'- X<sub>1</sub>X<sub>2</sub>TGCGTCGATGCAGGGGGG -3'; (SEQ ID NO:16);  
5'- X<sub>1</sub>X<sub>2</sub>TGCGCCGGCGCAGGGGGG-3';(SEQ ID NO:17);  
5'- X<sub>1</sub>X<sub>2</sub>TGCGCCGATGCAGGGGGG-3'(SEQ ID NO:18);  
5'- X<sub>1</sub>X<sub>2</sub>TGCATCGACGCAGGGGGG-3'(SEQ ID NO:19); or.  
5'- X<sub>1</sub>X<sub>2</sub>TGCGTCGGTGCAGGGGGG-3'(SEQ ID NO:20),

wherein X<sub>1</sub> is a G or not base and X<sub>2</sub> is a G or no base.

Claim 12 (original): The oligodeoxynucleotide of claim 1, comprising any one of  
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1);  
AAGGTCAACG TTGAAAAAAA (SEQ ID NO: 35);  
GGTGCATCGATGCAGGGGGG (SEQ ID NO: 1); GGTGCATCGATGCAGGGGGG  
(SEQ ID NO: 1); GGTGCGTCGACGCAGGGGGG SEQ ID NO: 31);  
GGTGCCTCGATGCAGGGGGG (SEQ ID NO: 7); GGTGCACCGGTGCAGGGGGG  
(SEQ ID NO: 2);  
GTCGACGTCGAC (SEQ ID NO: 54);  
GGTGCATCGATGCAGGGGG (SEQ ID NO: 73);  
GGCGTCGACG GGG (SEQ ID NO: 74);

GGTGCATCGATGCGAGAGA (SEQ ID NO: 87);  
TCGGATGTTCTC (SEQ ID NO: 113), or  
GGTCCATCGATCCAGGGGG (SEQ ID NO: 138).

Claim 13 (original): The oligodeoxynucleotide of any of claim 1, wherein the oligodeoxynucleotide is modified to prevent degradation.

Claim 14 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide has a phosphate backbone modification.

Claim 15 (original): The oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

Claim 16 (original): The oligodeoxynucleotide of claim 1, wherein the oligodeoxynucleotide comprises about 100 nucleotides or less.

Claim 17 (original): The oligodeoxynucleotide of claim 16, wherein the oligodeoxynucleotide comprises about 50 nucleotides or less.

Claim 18 (original): The oligodeoxynucleotide of claim 9, wherein the oligodeoxynucleotide comprises about 18 to about 30 nucleotides.

Claim 19 (original): An oligodeoxynucleotide delivery complex comprising the oligodeoxynucleotide of claim 1 and a targeting moiety.

Claim 20 (original): The oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

Claim 21 (original): The oligodeoxynucleotide of delivery complex of claim 19, wherein the oligodeoxynucleotide and the targeting moiety are covalently linked.

Claim 22 (original): A pharmacological composition comprising the oligodeoxynucleotide of claim 1 and a pharmacologically acceptable carrier.

Claim 23-59 (canceled).